Royalty Pharma plc (NASDAQ:RPRX)
| Market Cap | 24.61B+54.1% |
| Revenue (ttm) | 2.54B+10.0% |
| Net Income | 815.30M-20.1% |
| EPS | 1.74-19.4% |
| Shares Out | 443.27M |
| PE Ratio | 23.32 |
| Forward PE | 9.65 |
| Dividend | $0.93(1.65%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 746,825 |
| Open | 56.57 |
| Previous Close | 56.76 |
| Day's Range | 55.13 - 56.71 |
| 52-Week Range | 35.23 - 64.38 |
| Beta | 0.41 |
| Analysts | Buy |
| Price Target | 63.33(+14.09%) |
| Earnings Date | Nov 4, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About RPRX
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$RPRX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in RPRX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by RPRX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
RPRX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New RPRX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to RPRX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in RPRX
| ETF | Est. Holding Size |
|---|---|
| VXFVanguard Extended Market ETF | $278.19M |
| VFLOVictoryShares Free Cash Flow ETF | $179.81M |
| VYMVanguard High Dividend Yield ETF | $103.04M |
| IWRiShares Russell Mid-Cap ETF | $97.08M |
| IHEiShares U.S. Pharmaceuticals ETF | $66.16M |
| CGDGCapital Group Dividend Growers ETF | $65.98M |
Estimated from each fund’s disclosed top holdings × AUM
RPRX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from RPRX’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score